KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Cash & Current Investments (2017 - 2025)

Historic Cash & Current Investments for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to $5.3 billion.

  • Takeda Pharmaceutical's Cash & Current Investments fell 656.83% to $5.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.3 billion, marking a year-over-year decrease of 656.83%. This contributed to the annual value of $4.8 billion for FY2025, which is 4739.81% up from last year.
  • Per Takeda Pharmaceutical's latest filing, its Cash & Current Investments stood at $5.3 billion for Q4 2025, which was down 656.83% from $5.1 billion recorded in Q3 2025.
  • Over the past 5 years, Takeda Pharmaceutical's Cash & Current Investments peaked at $11.2 billion during Q2 2021, and registered a low of $3.2 billion during Q1 2024.
  • Moreover, its 5-year median value for Cash & Current Investments was $5.7 billion (2024), whereas its average is $6.8 billion.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first surged by 5786.42% in 2021, then tumbled by 4440.37% in 2023.
  • Over the past 5 years, Takeda Pharmaceutical's Cash & Current Investments (Quarter) stood at $10.5 billion in 2021, then decreased by 24.37% to $8.0 billion in 2022, then tumbled by 31.75% to $5.4 billion in 2023, then grew by 3.55% to $5.6 billion in 2024, then decreased by 6.57% to $5.3 billion in 2025.
  • Its last three reported values are $5.3 billion in Q4 2025, $5.1 billion for Q3 2025, and $4.7 billion during Q2 2025.